CRVS Stock Price, Corvus Pharmaceuticals Quote, Chart

Market Summary

USD1.45-0.03

Market Closed

-2.03%

CRVS Stock Price

View Fullscreen

CRVS RSI Chart

CRVS Valuation

Market Cap

71.1M

Price/Earnings (Trailing)

-2.63

Price/Sales (Trailing)

911.61

Price/Free Cashflow

-2.97

CRVS Price/Sales (Trailing)

CRVS Profitability

Return on Equity

-69.87%

Return on Assets

-59.34%

Free Cashflow Yield

-33.71%

CRVS Fundamentals

CRVS Revenue

Revenue (TTM)

78.0K

Rev. Growth (Yr)

-85.14%

Rev. Growth (Qtr)

-43.59%

CRVS Earnings

Earnings (TTM)

-27.0M

Earnings Growth (Yr)

32.22%

Earnings Growth (Qtr)

-10.88%

Breaking Down CRVS Revenue

Last 7 days

3.6%

Last 30 days

-19.0%

Last 90 days

-29.3%

Trailing 12 Months

27.2%

How does CRVS drawdown profile look like?

CRVS Financial Health

Current Ratio

4.07

CRVS Investor Care

Shares Dilution (1Y)

5.30%

Diluted EPS (TTM)

-0.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	497.0K	0	287.5K	78.0K
2022	323.0K	411.0K	499.0K	587.0K
2021	0	0	0	235.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Corvus Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 15, 2023	grais linda	bought	24,500	2.45	10,000	-
Dec 20, 2022	jones william benton	bought	15,800	0.79	20,000	see remarks
Dec 14, 2022	lea leiv	bought	3,364	0.841	4,000	chief financial officer
Dec 14, 2022	miller richard a md	bought	7,812	0.7812	10,000	president and ceo
Dec 13, 2022	lea leiv	bought	22,275	0.7425	30,000	chief financial officer
Dec 13, 2022	miller richard a md	bought	37,015	0.7403	50,000	president and ceo
Sep 28, 2022	miller richard a md	bought	19,070	0.7628	25,000	president and ceo
Sep 20, 2022	miller richard a md	bought	16,253	0.812662	20,000	president and ceo
Jun 27, 2022	miller richard a md	bought	4,984	0.9969	5,000	president and ceo
Jun 24, 2022	miller richard a md	bought	5,150	1.03	5,000	president and ceo

Which funds bought or sold CRVS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-81.17	-71,000	16,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-37,345	-	-%
Apr 23, 2024	Masso Torrence Wealth Management Inc.	unchanged	-	200	17,800	0.01%
Apr 16, 2024	JACKSON SQUARE CAPITAL, LLC	unchanged	-	1,276	113,516	0.03%
Apr 09, 2024	Northwest Capital Management Inc	unchanged	-	68.00	6,047	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.27	410,593	2,377,110	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-72,013	-	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-25,000	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	40,647	40,647	-%
Feb 15, 2024	BARCLAYS PLC	reduced	-99.99	-20,000	-	-%

Are Funds Buying or Selling CRVS?

Are funds buying CRVS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CRVS

No. of Funds

Unveiling Corvus Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	samlyn capital, llc	5.1%	2,496,259	SC 13G
Feb 13, 2024	miller richard a md	7.19%	3,684,010	SC 13G/A
Feb 14, 2023	tang capital partners lp	0.0%	0	SC 13G/A
Feb 13, 2023	chi advisors llc	5.12%	2,384,402	SC 13G
Feb 10, 2023	miller richard a md	6.45%	3,105,121	SC 13G/A
Jan 30, 2023	integrated core strategies (us) llc	4.1%	1,888,732	SC 13G/A
Feb 14, 2022	miller richard a md	5.45%	2,607,148	SC 13G/A
Feb 14, 2022	venrock healthcare capital partners ii, l.p.	0.5%	250,000	SC 13G/A
Feb 14, 2022	tang capital partners lp	6.7%	3,101,709	SC 13G/A
Feb 14, 2022	biotechnology value fund l p	1.6%	730,485	SC 13G/A

Recent SEC filings of Corvus Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Mar 19, 2024	8-K	Current Report
Mar 19, 2024	10-K	Annual Report
Mar 01, 2024	4	Insider Trading
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 08, 2024	3	Insider Trading
Jan 23, 2024	8-K	Current Report

Peers (Alternatives to Corvus Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Corvus Pharmaceuticals Inc News

Latest updates

Corvus Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	-43.6%	22,000	39,000	56,000	148,000	147,000	146,000	146,000	120,000	94,000
Operating Expenses	1.6%	5,651,000	5,560,000	6,574,000	5,666,000	12,473,000	7,013,000	7,413,000	6,810,000	9,047,000
S&GA Expenses	3.6%	1,652,000	1,595,000	1,980,000	1,586,000	2,108,000	2,090,000	2,313,000	2,022,000	2,056,000
R&D Expenses	0.9%	3,999,000	3,965,000	4,594,000	4,080,000	10,365,000	4,923,000	5,100,000	4,788,000	6,991,000
EBITDA Margin	-	-	-	-	-	-	-80.41	-83.01	-182	-
EBT Margin	-	-	-	-	-	-	-81.13	-83.80	-184	-
Net Income	-10.9%	-6,653,000	-6,000,000	-7,873,000	-9,816,000	-14,831,000	-8,363,000	-8,297,000	-9,236,000	-10,673,000
Net Income Margin	-15.5%	-346	-299	-331	-282	-242	-191	-187	-184	-
Free Cashflow	4.9%	-5,167,000	-5,434,000	-8,145,000	-7,547,000	-7,194,000	-6,123,000	-6,424,000	-6,856,000	-8,425,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-12.3%	46.00	52.00	58.00	58.00	68.00	80.00	93.00	101	109	119	109	109	86.00	56.00	64.00	74.00	84.00	92.00	103	112	118
Current Assets	-15.5%	28.00	33.00	38.00	36.00	44.00	51.00	59.00	64.00	71.00	79.00	69.00	69.00	45.00	53.00	61.00	70.00	79.00	88.00	98.00	107	116
Cash Equivalents	-37.2%	13.00	20.00	8.00	10.00	13.00	25.00	28.00	31.00	63.00	72.00	59.00	45.00	16.00	23.00	21.00	23.00	5.00	9.00	30.00	39.00	39.00
Net PPE	-10.6%	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00
Liabilities	-10.2%	7.00	8.00	9.00	9.00	12.00	16.00	12.00	12.00	12.00	14.00	13.00	15.00	13.00	14.00	13.00	14.00	13.00	12.00	13.00	12.00	8.00
Current Liabilities	-5.9%	7.00	7.00	8.00	8.00	11.00	14.00	10.00	9.00	10.00	11.00	12.00	14.00	12.00	12.00	12.00	12.00	10.00	10.00	11.00	9.00	7.00
Shareholder's Equity	-12.7%	39.00	44.00	49.00	49.00	56.00	65.00	80.00	90.00	97.00	105	96.00	94.00	72.00	42.00	51.00	60.00	71.00	80.00	90.00	101	110
Retained Earnings	-2.0%	-334	-328	-322	-315	-307	-297	-283	-274	-266	-257	-246	-234	-223	-250	-240	-230	-217	-206	-195	-182	-170
Additional Paid-In Capital	0.2%	374	374	373	365	364	364	363	362	362	361	341	329	295	293	291	290	288	286	285	283	281
Shares Outstanding	0%	49.00	49.00	49.00	47.00	47.00	47.00	47.00	47.00	42.00	44.00	38.00	35.00	29.00	-	-	-	-	-	-	-	-
Float	-	-	-	84.00	-	-	-	34.00	-	-	-	65.00	-	-	-	44.00	-	-	-	66.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	4.9%	-5,167	-5,434	-5,223	-8,111	-7,524	-6,929	-6,123	-6,424	-6,841	-8,425	-12,647	-8,787	-8,207	-7,732	-9,486	-9,353	-8,510	-10,607	-9,214	-8,990	-8,257
Share Based Compensation	4.8%	572	546	537	492	620	658	675	739	738	1,096	1,173	1,225	1,236	1,283	1,383	1,845	1,748	1,749	1,898	1,953	1,805
Cashflow From Investing	-113.2%	-2,318	17,546	-4,289	4,602	-3,882	3,040	3,140	-25,574	-1,999	3,471	15,242	4,846	463	9,939	6,670	27,697	4,595	-10,525	416	8,769	6,534
Cashflow From Financing	-100.0%	-	335	7,516	4.00	-	-	-	-	18.00	18,334	11,216	32,590	1,223	64.00	-	-	2.00	16.00	5.00	1.00	172

CRVS Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 16,526	$ 24,468	$ 29,115
General and administrative	6,881	8,097	9,515
Total operating expenses	23,407	32,565	38,630
Loss from operations	(23,407)	(32,565)	(38,630)
Interest income and other expense, net	1,584	654	(15)
Gain on sale of property and equipment		22
Sublease income - related party	78	587	235
Loss from equity method investment	(5,284)	(10,005)	(4,831)
Net loss	$ (27,029)	$ (41,307)	$ (43,241)
Net loss per share, basic	$ (0.56)	$ (0.89)	$ (1.03)
Net loss per share, diluted	$ (0.56)	$ (0.89)	$ (1.03)
Shares used to compute net loss per share, basic	48,025,274	46,553,511	41,854,110
Shares used to compute net loss per share, diluted	48,025,274	46,553,511	41,854,110
Other comprehensive loss:
Unrealized gain (loss) on marketable securities	$ 66	$ (48)	$ (7)
Cumulative foreign currency translation adjustment	(470)	(2,384)	1,872
Comprehensive loss	$ (27,433)	$ (43,739)	$ (41,376)

CRVS Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 12,620	$ 13,159
Marketable securities	14,529	29,144
Accounts receivable - related party	26	588
Prepaid and other current assets	781	773
Total current assets	27,956	43,664
Property and equipment, net	236	353
Operating lease right-of-use asset	1,149	2,217
Investment in Angel Pharmaceuticals	16,123	21,877
Other assets	89	129
Total assets	45,553	68,240
Current liabilities:
Accounts payable	1,525	1,976
Operating lease liability	1,374	1,228
Accrued and other liabilities	3,970	7,548
Total current liabilities	6,869	10,752
Operating lease liability		1,373
Total liabilities	6,869	12,125
Commitments and contingencies (Note 13)
Stockholders' equity:
Preferred stock: $0.0001 par value; 10,000,000 shares authorized at December 31, 2023 and December 31, 2022; 0 shares issued and outstanding at December 31, 2023 and December 31, 2022
Common stock: $0.0001 par value; 290,000,000 shares authorized at December 31, 2023 and December 31, 2022; 49,038,582 and 46,553,511 shares issued and outstanding at December 31, 2023 and December 31, 2022	5	5
Additional paid-in capital	374,363	364,361
Accumulated other comprehensive loss	(967)	(563)
Accumulated deficit	(334,717)	(307,688)
Total stockholders' equity	38,684	56,115
Total liabilities and stockholders' equity	$ 45,553	$ 68,240

About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

CEO	Dr. Richard A. Miller M.D.
WEBSITE	corvuspharma.com
INDUSTRY	Biotechnology
EMPLOYEES	29

Corvus Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Corvus Pharmaceuticals Inc? What does CRVS stand for in stocks?

CRVS is the stock ticker symbol of Corvus Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Corvus Pharmaceuticals Inc (CRVS)?

As of Fri Apr 26 2024, market cap of Corvus Pharmaceuticals Inc is 71.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRVS stock?

You can check CRVS's fair value in chart for subscribers.

What is the fair value of CRVS stock?

You can check CRVS's fair value in chart for subscribers. The fair value of Corvus Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Corvus Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRVS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Corvus Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether CRVS is over valued or under valued. Whether Corvus Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Corvus Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRVS.

What is Corvus Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, CRVS's PE ratio (Price to Earnings) is -2.63 and Price to Sales (PS) ratio is 911.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRVS PE ratio will change depending on the future growth rate expectations of investors.